Aptahem operates in the pharmaceutical industry. The company develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's lead candidate is being developed as an emergency drug intended to prevent the onset of life-threatening organ and tissue damage in patients suffering from sepsis. A large part of the research is carried out in collaboration with partners in the industry. The company was founded in 2014 and is headquartered in Malmö.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 7,38 | 7,38 | 2026-06-26 |
| Investment Aktiebolaget Balticum | 3,91 | 3,91 | 2026-06-26 |
| Magnus Renck | 2,50 | 2,50 | 2026-06-26 |
| Ivar Nordqvist | 1,92 | 1,92 | 2026-06-26 |
| Gilbert Langkjaer | 1,56 | 1,56 | 2026-06-26 |
| Per Bergström | 1,34 | 1,34 | 2026-06-26 |
| Björn Cyreus | 1,16 | 1,16 | 2026-06-26 |
| Scan-Merger AS | 1,13 | 1,13 | 2026-06-26 |
| Peter Cederström | 1,12 | 1,12 | 2026-06-26 |
| Göran Tennbäck | 1,11 | 1,11 | 2026-06-26 |
2026-11-26 Interim Report 2026-Q3
